~~<i id='F58EA047CE'><strike id='F58EA047CE'><tt id='F58EA047CE'><pre id='F58EA047CE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：knowledge 2025-09-05 11:17:15 - browse：8821

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

hotspot

focus

explore

leisure time

Editor’snote:Alivestreamoftheeventisembeddedbelow.Enoughtalkaboutfairness,safety,andeffective

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Testing for cancer recurrence creates a new limbo for patients

Hospitals warn Medicare's drug payment fix is ‘unlawful’

FDA has safety concerns on CRISPR

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Testing for cancer recurrence creates a new limbo for patients

explore

entertainment

focus

Supreme Court strikes down use of affirmative action

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical leaders decry Supreme Court decision on affirmative action

Biotech stock slump in 2023: awaiting the turnaround

How one medical school became remarkably diverse

FDA has safety concerns on CRISPR

Virginia high school admissions case could be legal follow

It's been 20 years since Dolly the sheep. Where's my clone?

Supreme Court strikes down use of affirmative action

Emergency workers more likely to restrain Black patients: study

hotspot

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Experts study whether long Covid risk adds up with each reinfection

The pink breast cancer awareness ribbon needs a redesign

Cassava reveals details — and problems — with Alzheimer's study

How AI helped researchers track recovery from depression

WHO may add ‘noma' to its list of neglected tropical diseases

focus

explore

explore

leisure time